Comparative Treatment of <i>Helicobacter pylori</i>–Positive Duodenal Ulcer Using Pantoprazole at Low and High Doses Versus Omeprazole in Triple Therapy

Crea, Filippo; Branciforte, G; Catanzaro, R; Bentivegna, C; Cipolla, R; Nuciforo, G.; Brogna, A.

doi:10.1046/j.1523-5378.1999.99274.x

Cited by 33 publications

(24 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our previous H. pylori eradication trials, we have demonstrated that double doses of PPIs were effective in inducing H. pylori -positive duodenal ulcer, while rabeprazole has shown to be efficacious in single dose (20 mg daily) as well as in double dose (40 mg daily), achieving an eradication and a healing rate as satisfactory as that of double-dose rabeprazole (40 mg) and omeprazole (40 mg daily) [10, 11, 12]. Several randomised controlled trials have compared short versus longer treatments [5, 29, 30, 31], but among these, only two studies comparing 2/4 days with 7/10 days have shown a significant difference [32, 33, 34].…”

Section: Discussionmentioning

confidence: 99%

“…Various triple-therapy regimens, consisting in the association of a proton pump inhibitor (PPI) with two antimicrobials (clarithromycin, amoxicillin or metronidazole), have been reported to be effective and a high eradication rate of these different drug combinations have been confirmed in Western countries [5, 6, 7]. More recently, higher doses of PPI, such as lansoprazole- or pantoprazole-based triple therapy, have been shown to be more effective than low doses of PPI in many reports [4, 7, 8, 9, 10, 11, 12]. Rabeprazole, the new member of the class of substituted benzimidazole molecules, is a potent antisecretory agent, suppressing both basal and stimulated gastric acid secretion in a dose-dependent manner [13, 14, 15].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Eradication Therapy with Rabeprazole versus Omeprazole in the Treatment of Active Duodenal Ulcer

Crea

Terminella²,

Branciforte³

et al. 2002

Digestion

View full text Add to dashboard Cite

Background: Rabeprazole has been demonstrated to be a potent antisecretory agent and has been shown to be clinically effective in the treatment of acid-related diseases. Aims: It was to determine the efficacy of rabeprazole at 20 and 40 mg in addition to amoxicillin and clarithromycin in the treatment of active Helicobacter pylori-positive duodenal ulcers compared with omeprazole 40 mg. Patients and Methods: One hundred and twenty-seven patients were randomised into three treatment groups: 40 patients were treated with rabeprazole 40 mg daily, 42 patients with rabeprazole 20 mg daily and 45 patients with omeprazole 40 mg daily for 10 days. All patients received amoxicillin 1 g twice a day and clarithromycin 500 mg twice a day for 5 days. All patients were re-assessed at least 4 weeks after the end of the treatment. Results: According to the intention-to-treat (ITT) protocol, ulcer healing was observed in 90% of patients in the rabeprazole 40 group, in 85.7% in the rabeprazole 20 group and in 93.3% in the omeprazole 40 group. We observed H. pylori eradication in 90% ITT in the rabeprazole 40 group, in 80.9% ITT in the rabeprazole 20 group and in 88.8% ITT in the omeprazole 40 group. Statistical analysis did not show significant differences among the three groups. Conclusions: A 10-day rabeprazole 20 mg regimen represents an efficacious and safe regimen for H. pylori eradication and ulcer healing.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Eradication Therapy with Rabeprazole versus Omeprazole in the Treatment of Active Duodenal Ulcer

Crea

Terminella²,

Branciforte³

et al. 2002

Digestion

View full text Add to dashboard Cite

show abstract

“…[87] The major result of the aforementioned metaanalysis comparing pantoprazole with other PPIs (such as omeprazole or lansoprazole) as eradication therapy against H. pylori is that the results are the same regardless of the PPI used. [78] Thus, as graphically presented in figure 2 derived from the seven studies [88][89][90][91][92][93][94] included in the meta-analysis in which 534 patients received pantoprazole and 603 patients received other PPIs, the mean H. pylori eradication rate was 83% and 81%, respectively. The OR for this comparison was exactly 1 (95% CI, 0.61-1.64).…”

Section: Pantoprazolementioning

confidence: 99%

“…Intention-to-treat analysis. [88][89][90][91][92][93][94] OR ¼ odds ratio; 95% CI ¼ 95% confidence interval.…”

Section: Rabeprazolementioning

confidence: 99%

Potent Gastric Acid Inhibition in Helicobacter pylori Eradication

Gisbert

2005

Drugs

View full text Add to dashboard Cite

At present, antisecretory drugs -foremost among them the proton pump inhibitors (PPIs) -represent a keystone in Helicobacter pylori eradication therapy. The present article shall first compare the role of PPIs as compared with histamine H 2 receptor antagonists, both of them in the role of antibiotic-associated antisecretory therapy, and shall then address the contribution of each of the various PPIs that have been developed until the present time to the H. pylori eradication therapies. In summary, it may be concluded that PPIs are more effective overall than H 2 receptor antagonists when the two groups of antisecretory drugs are given at the usual standard doses together with antibiotics with the intention of eradicating H. pylori infection. However, all PPIs (omeprazole, lansoprazole, pantoprazole, rabeprazole, and esomeprazole) are equivalent when given together with two antibiotics to cure the infection.

show abstract

“…2. Studies comparing pantoprazole-versus omeprazole-based triple therapies [8,11,13,14]. *Omeprazole or other PPI different from pantoprazole.…”

Section: Esomeprazolementioning

confidence: 99%

<i>Helicobacter pylori</i> Therapy: First-Line Options and Rescue Regimen

Gisbert

Jm²

2001

Dig Dis

View full text Add to dashboard Cite

In the present paper, several points regarding Helicobacter pylori treatment are reviewed, with the following conclusions: (1) all different proton pump inhibitors (PPIs) are equivalent when prescribed with antibiotics; (2) ranitidine bismuth citrate is equal to or, in some cases with antibiotic resistance, more effective than PPI; (3) previous treatment with PPI does not seem to affect the rate of eradication obtained with PPI plus two antibiotics; (4) just 1 week of PPI is enough to obtain duodenal ulcer healing, provided that H. pylori eradication is achieved; (5) the eradication rates seem to be higher in peptic ulcer than in nonulcer dyspepsia; (6) in areas where the prevalence of metronidazole resistance is high, triple therapy including a PPI, clarithromycin, and amoxicillin is the best option, and (7) quadruple therapy (PPI, bismuth, tetracycline, and metronidazole) is the recommended second-line therapy after PPI-clarithromycin-amoxicillin failure, although replacing the PPI and the bismuth compound by ranitidine bismuth citrate achieves also good results.

show abstract

Comparative Treatment of Helicobacter pylori–Positive Duodenal Ulcer Using Pantoprazole at Low and High Doses Versus Omeprazole in Triple Therapy

Cited by 33 publications

References 28 publications

Eradication Therapy with Rabeprazole versus Omeprazole in the Treatment of Active Duodenal Ulcer

Eradication Therapy with Rabeprazole versus Omeprazole in the Treatment of Active Duodenal Ulcer

Potent Gastric Acid Inhibition in Helicobacter pylori Eradication

<i>Helicobacter pylori</i> Therapy: First-Line Options and Rescue Regimen

Contact Info

Product

Resources

About